These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15662559)

  • 1. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
    Kim H; Haluzik M; Gavrilova O; Yakar S; Portas J; Sun H; Pajvani UB; Scherer PE; LeRoith D
    Diabetologia; 2004 Dec; 47(12):2215-25. PubMed ID: 15662559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes.
    Zhao H; Yakar S; Gavrilova O; Sun H; Zhang Y; Kim H; Setser J; Jou W; LeRoith D
    Diabetes; 2004 Nov; 53(11):2901-9. PubMed ID: 15504971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
    Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
    J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
    Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
    Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone action is independent of adipose tissue.
    Burant CF; Sreenan S; Hirano K; Tai TA; Lohmiller J; Lukens J; Davidson NO; Ross S; Graves RA
    J Clin Invest; 1997 Dec; 100(11):2900-8. PubMed ID: 9389757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
    Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
    Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects.
    Hammarstedt A; Sopasakis VR; Gogg S; Jansson PA; Smith U
    Diabetologia; 2005 Jan; 48(1):96-104. PubMed ID: 15624096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of adipocyte beta3-adrenergic receptor activation on the type 2 diabetic MKR mice.
    Kim H; Pennisi PA; Gavrilova O; Pack S; Jou W; Setser-Portas J; East-Palmer J; Tang Y; Manganiello VC; Leroith D
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1227-36. PubMed ID: 16682489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
    Tiikkainen M; Häkkinen AM; Korsheninnikova E; Nyman T; Mäkimattila S; Yki-Järvinen H
    Diabetes; 2004 Aug; 53(8):2169-76. PubMed ID: 15277403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
    Kim H; Haluzik M; Asghar Z; Yau D; Joseph JW; Fernandez AM; Reitman ML; Yakar S; Stannard B; Heron-Milhavet L; Wheeler MB; LeRoith D
    Diabetes; 2003 Jul; 52(7):1770-8. PubMed ID: 12829645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential insulin sensitizing and glucose lowering effects of a novel indole derivative in vitro and in vivo.
    Li YY; Wu HS; Tang L; Feng CR; Yu JH; Li Y; Yang YS; Yang B; He QJ
    Pharmacol Res; 2007 Oct; 56(4):335-43. PubMed ID: 17889553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
    Chao L; Marcus-Samuels B; Mason MM; Moitra J; Vinson C; Arioglu E; Gavrilova O; Reitman ML
    J Clin Invest; 2000 Nov; 106(10):1221-8. PubMed ID: 11086023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
    Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
    Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
    Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
    Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.